09:21 AM EST - Oncolytics Biotech Inc : Announced it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research. The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma as part of GCAR's anticipated master protocol for metastatic pancreatic cancer. Activities are currently underway to finalize the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data. Oncolytics Biotech Inc
shares T.ONC are trading up $0.02 at $1.62.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=5720347408572944
